Shares of Teva Pharmaceutical Industries (TEVA) surged 15.52% in pre-market trading on Wednesday following the release of its impressive third-quarter results and updated guidance for 2025. The Israel-based pharmaceutical giant delivered a strong performance that exceeded analyst expectations, driven by robust sales of its key branded drugs.

Teva reported third-quarter non-GAAP earnings of $0.78 per diluted share, up from $0.69 a year earlier and significantly above the FactSet consensus estimate of $0.68. Revenue for the quarter rose 3% to $4.48 billion, surpassing analyst projections of $4.34 billion. The company's performance was bolstered by strong sales of its trio of branded drugs targeting migraines, Huntington's disease, and schizophrenia.

Adding to investor optimism, Teva raised its 2025 earnings guidance. The company now expects adjusted earnings per share in the range of $2.55 to $2.65, up from its previous forecast of $2.50 to $2.65. While Teva slightly narrowed its 2025 revenue projection to $16.8-$17.0 billion from $16.8-$17.2 billion, the market responded positively to the overall financial outlook. The company's CEO also mentioned a "clear path" to achieving a 30% operating margin by 2027, further boosting investor confidence in Teva's long-term prospects.